German CureVac vaccine only 48% effective against Covid-19, final result shows

The result had been expected after discouraging interim results of clinical trials were published in mid-June. The lab said at the time that it was due to the rapid emergence of new variants.

RIO DE JANEIRO, BRAZIL - The German laboratory CureVac vaccine is only 48% effective against Covid-19, a level much lower than other messenger RNA immunizers approved, according to the full results of a large-scale clinical trial, the lab announced Wednesday, June 30.

In trial participants, "the prototype CVnCoV vaccine demonstrated an overall efficacy of 48% (83 cases in the vaccinated group, 145 in the placebo group) against the Covid-19 disease, irrespective of its severity," the lab said in a statement, which has signed a major contract with the European Union.

The result had been expected after discouraging interim . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?